

*In vivo* imaging of MMP-13 activity in the murine destabilised medial meniscus surgical model of osteoarthritis.

Ngee Han Lim<sup>1†</sup>, Ernst Meinjohanns<sup>2†</sup>, Morten Medal<sup>3</sup>, George Bou-Gharios<sup>1</sup>, Hideaki Nagase<sup>1</sup>

Supported by the Arthritis Research UK Centre for OA Pathogenesis, European Union's FP6 CAMP and FP7 LIVIMODE programmes and the NIH/NIAMS grant AR40994.

<sup>†</sup>Drs. Lim and Meinjohanns contributed equally to this work.

<sup>1</sup> Arthritis Research UK Centre for Osteoarthritis Pathogenesis, Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford University, United Kingdom

<sup>2</sup> Carlsberg Laboratory, Denmark

<sup>3</sup> Nano-Science Center, Department of Chemistry, University of Copenhagen, Denmark

Authors emails:

NH Lim: han.lim@kennedy.ox.ac.uk, E Meinjohanns: Ernst.Meinjohanns@dupont.com, G Bou-Gharios: george.gharios@kennedy.ox.ac.uk, M Medal: meldal@nano.ku.dk

Address correspondence and reprint requests to Hideaki Nagase, Professor of Matrix Biology, Kennedy Institute of Rheumatology, Oxford University, Roosevelt Drive, Headington, Oxford OX3 7FY, UK. E-mail: hideaki.nagase@kennedy.ox.ac.uk

Running Title: *In vivo* imaging of MMP-13 activity in murine osteoarthritis.

Keywords: osteoarthritis, MMP-13, imaging

## Abstract

**Objective.** To detect and determine disease severity of osteoarthritis using a probe activated by matrix metalloproteinase-13 (MMP-13) *in vivo* in the murine destabilised medial meniscus (DMM) surgical model of osteoarthritis.

**Design.** We have previously described *MMP12ap* and *MMP13ap*, internally quenched fluorescent peptide substrate probes that are activated respectively by MMP-12 and MMP-13. Here we used these probes to follow enzyme activity *in vivo* in mice knees 4, 6 and 8 weeks following DMM surgery. After *in vivo* optical imaging, disease severity was determined through traditional histological analysis. The amount of probe activation was analysed for discrimination between DMM, contralateral and sham operated knees, as well as for congruence between activity and histological damage.

**Results.** There was no specific activation of *MMP12ap* at the time points observed between sham operated and DMM operated, or their respective contralateral joints. The activation of the *MMP13ap* in the DMM model was highest 6 weeks after surgery, but was only specific compared against sham surgery 8 weeks after surgery (1.5-fold increase). The activation of *MMP13ap* correlated with histological damage 6 and 8 weeks after surgery, with correlations of 0.484 ( $p = 0.0032$ ) and 0.478 respectively ( $p = 0.0049$ ). This correlation dropped to 0.218 ( $p = 0.011$ ) if all data were considered.

**Conclusion.** The current MMP-13 activity probe is suitable for the discrimination between DMM and sham or contralateral knees 8 weeks after surgery, when cartilage loss is typified by the appearance of small fissures up to the tidemark, but not earlier. This activity correlates with the histological damage observed.

## 1 *Introduction*

2           Osteoarthritis (OA) is a multifactorial disease which leads to the destruction of the  
3 articular cartilage in joints and eventually the underlying subchondral bone. The search for an  
4 effective treatment of the disease is hampered by several factors. One of them is that disease  
5 is followed classically by radiographical measurement of joint space narrowing, which shows  
6 an advanced stage of tissue destruction where most of the articulating cartilage has been lost.  
7 To address this, increasing advances in MRI imaging techniques have been applied to follow  
8 cartilage degradation in the clinic; this allows earlier prognosis [1, 2]. It is, however, difficult  
9 to justify this expensive imaging modality in the pre-clinical development of drugs where a  
10 simple, but specific biochemical biomarker would suffice. However, there is still a lack of a  
11 robust biochemical biomarker for OA, with serum cartilage oligomeric protein levels being  
12 one of the most widely studied [3, 4]. Other biomarkers such as the breakdown products  
13 following proteolysis of the major cartilage components, type II collagen and aggrecan, in  
14 blood and urine have also been examined [5]. There is a clear need of both biomarkers and  
15 non-invasive imaging methods of detecting early cartilage degradation for both drug  
16 discovery and diagnosis of osteoarthritis.

17           The proteases responsible for the degradation of cartilage components are attractive  
18 targets for both biomarker and drug discovery, due to their established role in varied causes  
19 of OA. The major components of cartilage are the fibrillar type II collagen and the large  
20 aggregating proteoglycan, aggrecan. Members of the matrix metalloproteinase (MMP) and  
21 related adamalysin-like metalloproteinase with disintegrin and thrombospondin type I motifs  
22 (ADAMTS) family of proteases have been shown to be involved in this degradation [6]. In  
23 the destabilised medial meniscus (DMM) surgical model of OA, no degradation of aggrecan  
24 was observed in mice lacking functional ADAMTS-5 (aggrecanase-2) [7], whereas no  
25 degradation of collagen was observed in mice lacking MMP-13 (collagenase-3) [8]. Mice

1 lacking the protease cathepsin K also showed reduced cartilage damage in surgical models of  
2 OA [9]. However, it is still debatable whether this is a direct effect of cathepsin K  
3 degradation of collagen and aggrecan, or an indirect effect of cathepsin K upon the levels of  
4 ADAMTS-5 and MMP-13 in the joints of these mice. The ability to monitor the activity  
5 levels of these proteases during cartilage degradation may provide useful biomarkers of OA.

6 Advances in optical imaging technologies in conjunction with development of probes  
7 that are activated by proteases have enabled the detection of proteolysis *in vivo* [10]. Through  
8 the reverse design from MMP-specific inhibitors, we have developed substrate probes that are  
9 selectively cleaved by MMP-12 (macrophage elastase) and MMP-13 (collagenase 3) [11].  
10 These peptide substrate probes are flanked by a near-infrared fluorophore and quencher such  
11 that upon cleavage, fluorescence can be detected at tissue transparent wavelengths. These  
12 activity probes, *MMP12ap* and *MMP13ap*, were used to study MMP-12 and MMP-13  
13 activity in the development of arthritis in the collagen induced model of murine rheumatoid  
14 arthritis. The probes showed that MMP-12 activity was increased early during inflammation  
15 where macrophage infiltration is observed whereas MMP-13 activity was detected later  
16 during joint destruction.

17 Here we test the use of the *MMP12ap* and *MMP13ap* to detect and follow OA disease  
18 progression in the DMM model of OA. Given the smaller role of inflammation in the DMM  
19 compared to collagen-induced arthritis, we hypothesised that there would be lesser activation  
20 of *MMP12ap* compared with to *MMP13ap*. If the MMP-13 activity probe was successful in  
21 detecting and following OA disease, it would be a useful tool during the development of  
22 disease modifying drugs and the early detection of OA.

23

24

## 1    *Methods*

### 2    *Probes*

3    The *MMP12ap* (QSY-21-GPLG~LEEAK(Cy5.5)G-OH) and *MMP13ap* (QSY-21-  
4    GGPAG~LYEK(Cy5.5)G-OH) probes were prepared and characterized as previously  
5    described [11].

### 6    *Animal models*

7            Male C57 BL/6J mice aged 10 weeks were purchased from Harlan Laboratories  
8    (Blackthorn, Bicester, UK). Mice were housed in groups of 6 in individually vented cages,  
9    maintained at  $21 \pm 2$  °C on a 12-hour light/dark cycle and with food and water provided *ad*  
10   *libitum*. All experimental protocols were performed in compliance with the UK Animals  
11   (Scientific Procedures) Act 1986 regulations for the handling and use of laboratory animals  
12   (Home Office project licence PPL no: 70/6537).

13           The DMM surgery was performed on 10 week old male mice as described previously  
14   [12]. Briefly, following induction of anaesthesia by injection of 10 µl/g of  
15   Hypnorm<sup>®</sup>/Hypnovel<sup>®</sup> (at a ratio of 1:1 to 4 parts water), the right knee joint was accessed  
16   via a medial incision. The right meniscotibial ligament was transected, resulting in the release  
17   of the medial meniscus from its tibial attachment. Sham surgery consisted of medial  
18   capsulotomy of the right knee. All animals received buprenorphine HCl (Vetergesic; Alstoe  
19   Animal Health, York, UK) delivered sub-cutaneously immediately post surgery. A total of 82  
20   animals were used (divided equally into DMM and sham surgeries, 36 for the *MMP12ap*  
21   probe and 46 for the *MMP13ap* probe). Recovery from surgery was monitored daily by  
22   weight, visual inspection of wound healing and behaviour for two weeks. There was no  
23   difference in weight gain between groups observed throughout the experiment.

## 1    *Activation of probes in vivo*

2            Four, 6 and 8 weeks after surgery, 150 µl of 1 µM MMP-12ap or MMP-13ap was  
3    delivered intravenously via the tail vein. Two, 4 and 8 hours after injection, consecutive  
4    fluorescence images were obtained by exposing mice under gaseous anaesthesia (2.5% (v/v)  
5    isofluorane and O<sub>2</sub>) in a Kodak *In Vivo* FX Pro (Carestream, Woodbridge, USA), to a 630 nm  
6    excitation and capturing emission at 700 nm for 1 min. X-ray images were taken at the same  
7    time point for co-registration of signal to the knee joint, by exposure to X-rays for 20  
8    seconds.

## 9    *Image analysis*

10           Fluorescence images were analysed using the Carestream MI software (version 5.1,  
11    Carestream, Woodbridge, USA). Regions of interest (ROI) were defined as a circle of 65  
12    pixels for knees. The ROI for knees was centered in the joint space as visualised using co-  
13    registered X-ray images. The mean fluorescent intensity (MFI) of the ROI was then obtained.  
14    No background intensity was subtracted from the values.

## 15   *Histology and scoring of cartilage damage*

16           After images at the 8 hour time points were taken, mice were sacrificed by cervical  
17    dislocation and the knee joints were dissected and fixed in formalin (2% (v/v)) overnight,  
18    decalcified in EDTA for 5 weeks and embedded in paraffin. Serial sections 5 µm in thickness  
19    were cut. Every 10<sup>th</sup> section was stained with Safranin O for scoring cartilage damage.  
20    Scoring of the extent of cartilage damage in individual sections was done in accordance with  
21    the guidelines laid out in the OARSI histopathology initiative for small animals on a scale  
22    from 1 to 6 by two different observers [13]. All four quadrants of the section (medial tibial  
23    plateau, lateral tibial plateau, medial femoral chondyle, lateral femoral chondyle) are scored

individually and added for each histological section. The scores of the top three adjoining sections are added together to give the summed score (for a maximal score 72).

### *Statistical analysis*

All statistical analysis were performed with the software Prism (version 5.0, Graphpad Software, La Jolla, USA). Two way ANOVA with matched values and Bonferonni's post tests were used to analyse the data in Figure 3 and 4(A), paired student's t-tests were used to analyse the data in Figure 4(B) and Pearson's correlation without correction was used to analyse the data in Figure 5 (B-D).

### *Results*

#### *Progression of OA in the DMM model of OA*

Histological analysis indicated that there was significantly increased damage observed in the DMM animals from 4 weeks after surgery, which increased further at 6 and 8 weeks after surgery (Figure 1). These changes are comparable to those observed in DMM surgery performed elsewhere [12, 14].

#### *Probes in the DMM model of OA*

Co-registered X-ray images were used to define the ROI of the knee joint in the fluorescent images. The 65-pixel circular ROI used is marked in the X-ray images in Figure 2. Typical fluorescence images obtained using *MMP12ap* and *MMP13ap* are also shown in Figure 2. The amount of signal obtained from the knees using both probes was between 200 and 2000 mean fluorescence units. This was lower than the signal which we obtained using the probes in collagen induced arthritis [11].

1           There was no significant difference in the activation of *MMP12ap* between DMM  
2   operated knees and control knees at any of the time points observed (Figure 3, n = 6 in each  
3   group). The non-disease-specific activation of *MMP12ap* was highest at 4 weeks and  
4   decreased as time progressed in all groups of animals. This activation of *MMP12ap* is  
5   therefore most likely due to processes involved in the repair of the capsule of the knee joint in  
6   both DMM and sham surgeries.

7           Activation of *MMP13ap* was different from *MMP12ap* during the course of DMM. At  
8   the earliest time point, 4 weeks after surgery, there was no significant difference in probe  
9   activation between any of the groups at the 2, 4 and 8h time points (Figure 4A, top). This was  
10   also reflected when the signal difference between the operated and contralateral knee was  
11   calculated (Figure 4B, top). Six weeks after surgery, there was significant difference in the  
12   amount of activated probe detected between the DMM operated and its contralateral knees at  
13   the 2 hour time point according to 2-way ANOVA, but no significant difference between  
14   DMM operated and sham operated knees at any of the other time points (Figure 4A, middle).  
15   Furthermore, at 6 weeks, there was significant average difference of 400-600 units in the  
16   signal obtained from the DMM operated and its contralateral knees, whereas there was no  
17   difference between the sham operated and its contralateral knees (Figure 4B, middle). Eight  
18   weeks after surgery there was significant difference between the signals obtained from the  
19   DMM operated knees compared with either the contralateral knee or the sham operated knees  
20   4 hours after the injection of probe (Figure 4A, bottom). The significant average difference in  
21   signal between the operated and contralateral knees of the DMM operated animals was  
22   between 150-230 units throughout the time course (Figure 4B, bottom).

23           The earliest time at which *MMP13ap* could reliably distinguish the DMM operated  
24   knee from contralateral or sham operated knees was 8 weeks after surgery, with a 1.5-fold  
25   higher signal in the DMM knees compared to the controls. Earlier, at 6 weeks, the probe



could differentiate between operated and contralateral knees only if it was known *a priori* that DMM surgery had been performed. The amount of *MMP13ap* activation detected was highest 6 weeks after surgery (Figure 5A), indicating that the peak of detected MMP-13 activity occurred before the rise in histological damage. We have then examined whether there was any significant correlation between the activation of *MMP13ap* and histological damage in the knee joints, regardless if this damage was in the DMM, sham or contralateral groups. We found that there was no significant correlation between the activation of *MMP13ap* and histological damage 4 weeks after surgery (Figure 5B,  $r = 0.26$ ,  $p = 0.22$ ,  $n = 24$ ). However, there was significant correlation between activation of MMP13ap and histological damage separately at 6 and 8 weeks (Figure 5C and 5D), with a correlation,  $r$ , of 0.484 ( $p = 0.0032$ ,  $n = 36$ ) and 0.478 ( $p = 0.0049$ ,  $n = 32$ ) respectively. In addition, when all the data was combined, there was weak but significant correlation between the activation of *MMP13ap* and histological disease score throughout the time period studied ( $r = 0.263$ ,  $p = 0.011$ ,  $n = 92$ ). This indicates that histological tissue damage correlates with the activity of MMP-13 in the cartilage.

## Discussion

We have used two previously described activity probes for MMP-12 and MMP-13, *MMP12ap* and *MMP13ap* respectively, in the DMM model of murine OA to determine their utility in both disease diagnosis and disease severity. Inflammation plays a smaller role in the DMM model of OA, compared to the collagen-induced arthritis model of rheumatoid arthritis and this is reflected in the data obtained from *MMP12ap*. The lack of difference between the activation of *MMP12ap* in the DMM and sham operated groups of animals indicated there is no significant involvement of macrophage migration in the disease process at least at 4-8 weeks after the operation. The activation of *MMP13ap* however, discriminated between the DMM and controls 8 weeks after surgery, when cartilage damage is exemplified by small

fissure(s) extending to the tide mark of calcified cartilage. This represents a relatively early stage in the degeneration of the type II collagen fibrils. The activation of *MMP13ap* also correlated with histological damage separately at 6 and 8 weeks after surgery, but this correlation weakened when combined, due to the higher levels of *MMP13ap* activation at 6 weeks. This indicates that there may be a peak in MMP-13 activity, and that damage to the tissue past a certain point is reliant on other factors, such as mechanical wear. This work represents the first in-depth study linking detectable *in vivo* MMP-13 activity from joints with OA disease progression.

While the *MMP13ap* probe is capable of differentiating between DMM and sham surgeries in this study, it is currently unsuitable as a biomarker for OA disease, owing to the weak overall correlation between probe activation and histological damage. Other studies using peptide substrate probes to detect MMP-13 activity in OA joints have focused on intra-articular delivery of the probe in rats [15]. Intra-articular delivery is suitable for studies using surgical models of OA, as the timing and joint location of disease occurrence is known. However, for models of spontaneous OA [16], such as those involving the STR/ort mouse, or in larger animals such as the Duncan-Hartley guinea pigs, the ability to deliver probes intravenously becomes essential due to the unknown in both time and joint(s) affected. We have used this delivery route in this study with promising results. Improvements to the peptide probe described here, such as increased specificity, increased rate of cleavage by MMP-13 and increased retention in joint/ cartilage, needs to be explored in order to realise its potential as a biomarker for OA disease progression.

Apart from mice deficient in MMP-13, mice deficient in ADAMTS-5 are protected in the DMM model [7, 8]. An ADAMTS-5 activity probe may potentially serve as an earlier marker for OA, as aggrecan degradation is thought to be initiated before collagen degradation [17]. There is, however, a higher turnover of aggrecan in normal tissue compared to collagen

[18, 19], which may make it difficult to differentiate the normal vs. the pathological activity, limiting the utility of such an *in vivo* ADAMTS-5 probe.

Specific inhibitors for both ADAMTS-5 and MMP-13 are in development. Commonly used animal OA models in which the efficacies of these inhibitors are tested are those of the DMM or the anterior cruciate ligament injury model [20]. These models are well characterised in terms of where and when disease develops and how fast it progresses. Disease progression in human OA is currently unpredictable and the relative contributions of these proteolytic enzymes during this progression is not clear. Probes capable of detecting specific enzyme activity will allow us to start to address this. Additionally, they may provide time frames where particular inhibitor therapies, should be prescribed, as there may be a window where an ADAMTS-5 inhibitor will be effective and a different window where an MMP-13 inhibitor would be. Thus, concurrent development of ADAMTS-5 and MMP-13 activity probes and their use may guide future management of clinical OA.

#### *Acknowledgments*

The authors would like to thank Mino Medghalchi for her training in the DMM model and after surgery care.

#### *Author Contributions*

Corresponding author Hideaki Nagase, George Bou-Gharios and Morten Medal designed the project. Ngee Han Lim and Ernst Meinjohanns were involved with data acquisition and analysis, with George Bou-Gharios providing statistical expertise. Ngee Han Lim and Hideaki Nagase drafted the paper and all other authors reviewed the paper for important intellectual content. All the authors approved the final submitted version.

1    *Role of funding source*

2    This work was supported by the Arthritis Research UK Centre for OA Pathogenesis,  
3    European Union's FP6 CAMP and FP7 LIVIMODE programmes and the NIAMS/NIH grant  
4    AR40994.

5    *Conflict of Interest*

6    There has been no commercial finance involved in this work and the authors declare no  
7    financial conflicts of interest.

Figure Legends:

Figure 1: Histological progression of DMM in this study.

Typical histological sections of the DMM operated right knee joints stained with Safranin O obtained at (A) 4 weeks, (B) 6 weeks and (C) 8 weeks after surgery. Damaged areas within cartilage sections are indicated with arrows. (D) Summed histological scores obtained from addition of the scores of the top 3 consecutive scoring slides per knee. Data are mean  $\pm$  95% ci.

Figure 2: Representative images obtained 4 hours following intravenous injection of *MMP12ap* and *MMP13ap* in mice following sham and DMM surgery.

Typical X-ray and fluorescence images obtained 4 hours following intravenous injection of either 150  $\mu$ l of 1  $\mu$ M *MMP12ap* or *MMP13ap* after 4, 6 and 8 weeks after DMM or sham surgery. Left knees (LK), right knees (RK) and the red circle marking the ROI used for analysis are indicated. The fluorescence rainbow scales are indicated on the right.

Figure 3: Quantification of the activation of *MMP12ap* in the DMM model of OA

Mice were injected with 150  $\mu$ l of 1  $\mu$ M of *MM12ap* intravenously 4, 6 and 8 weeks after DMM or sham surgery. Images were taken 2, 4 and 8 hours after injection and used to quantify the MFI in the operated and contralateral knees. Whiskers depict the 95% ci. n = 6 for each group. Analysis by two-way ANOVA with Bonferroni post tests indicated no significant difference between any of the groups at any time points between the weeks.

1

2 Figure 4: Quantification of the activation of *MMP13ap* in the DMM model of OA

3 Mice were injected with 150  $\mu$ l of 1  $\mu$ M of the *MMP13ap* intravenously 4, 6 and 8 weeks

4 after DMM or sham surgery. Images were taken 2, 4 and 8 hours after injection and used to

5 quantify the MFI in the operated and contralateral knees (A). Whiskers depict the 95% ci. n =

6 6 for each group in week 4, n = 9 for each group in week 6 and n = 8 for each group in week

7 8. \*  $p < 0.05$  between DMM and other groups after two way ANOVA analysis with

8 Bonferroni post tests (DMM vs contra:  $p = 0.0477$ , DMM vs Sham:  $p = 0.0421$ , DMM vs

9 Sham contra:  $p = 0.0161$ ). (B) The difference in signal between the operated and contralateral

10 knees in the DMM and sham groups. \*  $p < 0.05$  by paired students  $t$  test, individual values as

11 indicated.

12

13 Figure 5: Longitudinal correlation of the signal from the *MMP13ap* in the progression of the

14 DMM model of OA

15 The MFI of the relevant ROIs obtained at 4 hours after injection of the *MMP13ap* was plotted

16 against either the duration after surgery (A) or the individual summed histological scores 4

17 weeks (B), 6 weeks (C) or 8 weeks (D) after surgery. \*  $p < 0.05$  between DMM and other

18 groups, as detailed in Figure 4. The Pearson correlation factor,  $r$  at  $p < 0.005$ , between mean

19 fluorescent signal and histological damage for weeks 6 and 8 are indicated.

20

## References

1. Binks DA, Hodgson RJ, Ries ME, Foster RJ, Smye SW, McGonagle D, et al. Quantitative parametric MRI of articular cartilage: a review of progress and open challenges. *The British journal of radiology* 2013; 86: 20120163.
2. Illingworth KD, El Bitar Y, Siewert K, Scaife SL, El-Amin S, Saleh KJ. Correlation of WOMAC and KOOS scores to tibiofemoral cartilage loss on plain radiography and 3 Tesla MRI: data from the osteoarthritis initiative. *Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA* 2013.
3. Hoch JM, Mattacola CG, Medina McKeon JM, Howard JS, Lattermann C. Serum cartilage oligomeric matrix protein (sCOMP) is elevated in patients with knee osteoarthritis: a systematic review and meta-analysis. *Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society* 2011; 19: 1396-1404.
4. Mobasheri A. Osteoarthritis year 2012 in review: biomarkers. *Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society* 2012; 20: 1451-1464.
5. Settle S, Vickery L, Nemirovskiy O, Vidmar T, Bendele A, Messing D, et al. Cartilage degradation biomarkers predict efficacy of a novel, highly selective matrix metalloproteinase 13 inhibitor in a dog model of osteoarthritis: confirmation by multivariate analysis that modulation of type II collagen and aggrecan degradation peptides parallels pathologic changes. *Arthritis Rheum* 2010; 62: 3006-3015.
6. Troeberg L, Nagase H. Proteases involved in cartilage matrix degradation in osteoarthritis. *Biochimica et biophysica acta* 2012; 1824: 133-145.
7. Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma HL, et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. *Nature* 2005; 434: 644-648.
8. Little CB, Barai A, Burkhardt D, Smith SM, Fosang AJ, Werb Z, et al. Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development. *Arthritis Rheum* 2009; 60: 3723-3733.
9. Kozawa E, Nishida Y, Cheng XW, Urakawa H, Arai E, Futamura N, et al. Osteoarthritic change is delayed in a Ctsk-knockout mouse model of osteoarthritis. *Arthritis and rheumatism* 2012; 64: 454-464.
10. Edgington LE, Verdoes M, Bogoy M. Functional imaging of proteases: recent advances in the design and application of substrate-based and activity-based probes. *Current opinion in chemical biology* 2011; 15: 798-805.
11. Lim NH, Meinjohanns E, Bou-Gharios G, Gompels LL, Nuti E, Rossello A, et al. In vivo imaging of matrix metalloproteinase 12 and matrix metalloproteinase 13 activities in the mouse model of collagen-induced arthritis. *Arthritis & rheumatology* 2014; 66: 589-598.
12. Chia SL, Sawaji Y, Burleigh A, McLean C, Inglis J, Saklatvala J, et al. Fibroblast growth factor 2 is an intrinsic chondroprotective agent that suppresses ADAMTS-5 and delays cartilage degradation in murine osteoarthritis. *Arthritis and rheumatism* 2009; 60: 2019-2027.
13. Glasson SS, Chambers MG, Van Den Berg WB, Little CB. The OARSI histopathology initiative - recommendations for histological assessments of osteoarthritis in the mouse. *Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society* 2010; 18 Suppl 3: S17-23.
14. Glasson SS, Blanchet TJ, Morris EA. The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. *Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society* 2007; 15: 1061-1069.
15. Lee S, Park K, Lee SY, Ryu JH, Park JW, Ahn HJ, et al. Dark quenched matrix metalloproteinase fluorogenic probe for imaging osteoarthritis development in vivo. *Bioconjugate chemistry* 2008; 19: 1743-1747.

16. Lampropoulou-Adamidou K, Lelovas P, Karadimas EV, Liakou C, Triantafillopoulos IK, Dontas I, et al. Useful animal models for the research of osteoarthritis. *European journal of orthopaedic surgery & traumatology : orthopedie traumatologie* 2013.
17. Pratta MA, Yao W, Decicco C, Tortorella MD, Liu RQ, Copeland RA, et al. Aggrecan protects cartilage collagen from proteolytic cleavage. *J Biol Chem* 2003; 278: 45539-45545.
18. Maroudas A, Bayliss MT, Uchitel-Kaushansky N, Schneiderman R, Gilav E. Aggrecan turnover in human articular cartilage: use of aspartic acid racemization as a marker of molecular age. *Archives of biochemistry and biophysics* 1998; 350: 61-71.
19. Maroudas A, Palla G, Gilav E. Racemization of aspartic acid in human articular cartilage. *Connect Tissue Res* 1992; 28: 161-169.
20. Little CB, Hunter DJ. Post-traumatic osteoarthritis: from mouse models to clinical trials. *Nature reviews. Rheumatology* 2013; 9: 485-497.







Figure 1




Figure 2





Figure 3





**(A)****(B) Operated - Contralateral**

Figure 4


(A)



**(B)**



(C)



**(D)**




Figure 5